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ABSTRACT 
Streptococcus pneumoniae is commonly found as an asymptomatic colonizer of the 
nasopharynx of children, but it can also translocate to normally sterile body sites and cause 
severe diseases, like pneumonia, septicemia or meningitis. Pneumococci spread via aerosols. 
Upon entry into the upper respiratory tract of the host, glycoconjugates with terminal sialic 
acids (Sias) are among the first structures pneumococci encounter. Hence, they play an 
important role in pneumococcal pathogenesis. Moreover, glycans are also implicated in the 
recognition of microbial pathogens by the innate immune system, as many ligands of Toll-
like receptors are glycoconjugates. Both aspects of glycan-based pneumococcal-host 
interactions were studied in this thesis. 
 
In most mammals, the Sia N-acetylneuraminic acid (Neu5Ac) is converted into N-
glycolylneuraminic acid (Neu5Gc) by the cytidine-monophosphate-N-acetylneuraminic acid 
hydroxylase (CMAH). However, humans lack Neu5Gc due to a deletion in CMAH, instead 
they overproduce Neu5Ac. We reported a faster disease progression in Cmah-/- versus wild-
type (wt) mice after pneumococcal challenge and an upregulation of pneumococcal sialidase 
NanA and the main sialic acid transporter SatABC in response to Neu5Ac as compared with 
Neu5Gc, which was mediated by the response regulator CiaR. 
Moreover, we detected higher pneumococcal adhesion rates to cells presenting Neu5Ac than 
Neu5Gc. In vitro, higher bacterial adherence downregulated IL-8 secretion, and in vivo, 
pneumococcal pyruvate oxidase (SpxB) and pneumolysin contributed to a reduced immune 
response in Cmah-/-
 
compared with wt mice after intranasal challenge.  
 
Influenza infections lead to changes in the pulmonary environment and sensitize for a 
pneumococcal infection. We observed higher protein concentrations, increased numbers of 
dead cells as well as upregulated hydrogen peroxide concentrations in bronchoalveolar 
lavages of influenza- versus mock-infected mice. The increased virus-mediated stress in the 
lower respiratory tract mediated an upregulation of the pneumococcal serine protease HtrA 
during influenza/pneumococcal coinfection. A mutant of HtrA was severely attenuated in a 
murine coinfection model, suggesting an important role of HtrA in pneumococcal outgrowth 
following primary influenza infection. 
 
Dendritic cells link the innate with the adaptive immune system. We found an RNA-mediated 
recognition of pneumococci by TLR3 in dendritic cells, which induced the secretion of the 
cytokine IL-12. Moreover, in influenza/pneumococcal coinfections, the virus upregulated 
TLR3 expression, which led to an enhanced production of IL-12 by dendritic cells. 
In summary, we show that glycan-mediated interactions of S. pneumoniae and the host play a 
major role in pneumococcal host tropism and strongly affect pneumococcal virulence, as well 
as innate immune responses.  
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1 INTRODUCTION 
 
1.1 Streptococcus pneumoniae 
 
In 1881, George Miller Sternberg and Louis Pasteur isolated diplococci after injecting human 
saliva into rabbits [1, 2]. In 1886, Fraenkel used the name Pneumococcus for the first time, 
referring to the pneumonia these bacteria cause. In the same decade, Christian Gram 
developed a staining to visualize bacteria in patient samples. He discovered lancet-shaped 
gram-positive cocci in the lung specimens of patients who died of pneumonia and named 
them “the cocci of croupous pneumonia”. In 1920, the isolate was given the name 
Diplococcus pneumoniae, due to its microscopic morphology, which was seen in the gram-
stain. It took until 1974 that these bacteria were referred to as Streptococcus pneumoniae [3]. 
However, the term “Pneumococcus” is still frequently used. 
 
Pneumococcal colonies appear to be small and greyish on blood agar plates after an overnight 
incubation at 37°C and 5% carbon dioxide (CO2). Moreover, they are α-hemolytic, as they 
oxidize hemoglobin. To date, we know of at least 97 different pneumococcal serotypes, 
which differ in the composition of their polysaccharide capsule [4]. The presence of the 
capsule leads to the mucoid appearance of pneumococcal colonies on solid agar. Another 
characteristic of most S. pneumoniae isolates is the sensitivity to optochin, which allows 
differentiating them from S. viridans [5, 6] (Figure 1). However, this test is not sufficient to 
identify pneumococci, since there have been recent reports of optochin-resistant isolates [7].  
 
 
Figure 1 Optochin sensitivity of the α-hemolytic S. pneumoniae TIGR4. TIGR4 was streaked out 
on a blood agar plate and cultured at 37°C in the presence of 5% CO2. The sensitivity to optochin was 
tested with a disk diffusion method. 
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S. pneumoniae was the first bacterium shown to be naturally competent. In 1928, Griffith 
showed that viable non-virulent pneumococci turned into virulent ones when they were 
injected into mice together with heat-killed pathogenic isolates. He hypothesized that the 
dead pneumococcal strain provides a certain protein that enables the attenuated bacteria to be 
virulent [8]. It took 16 more years to show that the exchanged substance, responsible for the 
increased virulence, was not protein, but deoxyribonucleic acid (DNA) [9]. 
 
 
1.1.1 Pneumococcal colonization and disease 
 
Pneumococci are human-adapted and often found asymptomatically colonizing the upper 
respiratory tract. Nonetheless, S. pneumoniae can cause diseases ranging from benign 
respiratory tract infections, e.g. sinusitis or otitis media, to severe diseases like pneumonia, 
septicaemia and even meningitis [10], making pneumococcal infections a major cause of 
global childhood mortality, leading to about 11% of all deaths among children below the age 
of five [11] (Figure 2). 
 
Figure 2 Pneumococcal mortalities of children younger than 5 years. The graph represents the 
number of deaths per 100 000 HIV-negative children caused by pneumococcal infections. The picture 
was adopted from [11]. 
 
 
  3 
Colonization 
Pneumococcal colonization is believed to occur via the spread of pneumococci-containing 
aerosols. Before their eventual clearance by the immune system, pneumococci can colonize 
the upper respiratory tract for several weeks or months [12]. Especially pre-school age 
children and those attending day care centers are found to be the main reservoir for S. 
pneumoniae [13, 14], with carriage rates up to 60% [10, 15]. Less than 10% of adults are 
carriers, although a higher colonization rate was found in parents of small children [16]. Once 
these bacteria establish colonization, they can replicate and form biofilms and/or translocate 
to other sites and cause disease. 
 
Otitis media and sinusitis 
S. pneumoniae is one of the causative agents of acute otitis media (AOM), an inflammation 
of the middle ear, affecting up to 85% of all children at the age of 3 years [17]. In Sweden 
and the US, AOM represents the most common infectious disease to prescribe antibiotics to 
children [18]. However, recurrent or persistent AOM can lead to complications and severe 
sequelae, e.g. conductive hearing loss, labyrinthitis, perforation of the tympanic membrane or 
even meningitis [19]. 
Although viruses cause most of the sinusitis infections, S. pneumoniae is among the most 
common bacterial agents that can lead to infections of the paranasal sinus cavity [20]. While 
most viral sinusitis episodes resolve completely after 10 days, bacterial rhinosinusitis is 
usually more persistent [21].  
 
Pneumonia 
Pneumococcal infections of normally sterile sites of the body, like the lower respiratory tract, 
the blood or meninges, are considered invasive pneumococcal diseases, also called IPD [22]. 
An inflammation of the lungs is called pneumonia. S. pneumoniae is the most common cause 
of community-acquired pneumonia (CAP), followed by Haemophilus influenzae, respiratory 
viruses or Mycoplasma pneumoniae [23]. CAP represents a huge financial and clinical 
burden throughout the whole world [24] and accounts for 19% of all mortality cases in 
children below the age of 5 years. The distribution of pneumonia-caused deaths differs 
greatly between geographical regions and their economic situation, with 50% of all 
pneumonia-related mortalities occurring in the African and only 2% - 3% in the European 
and American region [25]. 
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Bacteraemia and sepsis 
20-30% of the children with pneumonia develop bacteraemia, the occurrence of bacteria in 
the blood stream [26].  The consequence can be sepsis, a life-threatening systemic infection. 
CAP and health-care associated pneumonia in children and adults are the pre-conditions, 
which lead to 50% of all sepsis cases. Especially, very young children below 1 year of age 
and elderly people of more than 65 years of age are prone to develop sepsis [27]. 
 
Meningitis 
Since the introduction of the vaccine against H. influenzae type b, S. pneumoniae and 
Neisseria meningitidis present the major causes of bacterial meningitis in children nowadays 
[26, 28]. A study conducted in the US, observed that mortality rates in children were less than 
10%, but almost half of the surviving patients suffered from severe sequelae, like hearing 
loss, brain infarcts, brain abscesses or hydrocephalus [29]. European studies describe a 
fatality rate of 30% in adults after pneumococcal meningitis and cognitive deficits in 26% of 
the survivors [30, 31]. As it is the case for pneumonia, the mortality rates after pneumococcal 
meningitis are significantly higher in developing than in developed countries [11].  
 
Risk factors 
As discussed before, the age determines the risk of IPD, affecting especially very young 
children with their naïve immune system, elderly people of an age of more than 65 years due 
to their weakening immune response, and individuals with co-morbidities, e.g. diabetes or 
different immunodeficiencies [32]. Environmental and social factors, such as the number of 
siblings, financial income, and smoking affect pneumococcal colonization. Furthermore, the 
ethnic background was also shown to determine the risk of a pneumococcal infection, with 
African Americans and Native Americans having a high probability of developing IPD [33].  
Coinfections with viral pathogens, especially with influenza A virus (IAV, see below) and 
human immunodeficiency virus (HIV), have been shown to significantly promote 
pneumococcal infections [32, 34].  
 
Pneumococcal coinfection with Influenza A virus 
During influenza pandemics, most fatalities are not caused by the virus alone, but by a 
secondary infection with a bacterial pathogen [35]. In 1918, the “Spanish flu” was caused by 
subtype H1N1. This pandemic killed more than 50 million people, which primarily died due 
to superinfections with S. pneumoniae [36]. In 1957, IAV subtype H2N2 caused the “Asian 
flu”, leading to more than 1 million deaths partially due to pneumonia caused by 
Staphylococcus aureus. The severe and about 500 000 fatal cases of the “Hong Kong flu” in 
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1968 were mainly caused by co-infections of influenza subtype H3N2 and pneumococci [37-
39]. The next influenza pandemic occurred 41 years later, and is known as the so-called 
“swine flu”. In 2009, infections with H1N1 led to about 200 000 deaths with mainly young 
adults to be affected. Like former pandemics, severe cases and fatalities were mainly caused 
by S. aureus and S. pneumoniae [40]. Although it was first believed that the introduction of 
antibiotics against S. pneumoniae was responsible for the shift from secondary infections with 
pneumococci to co-infection with other pathogens, strain-related changes in the virus and/or 
the bacteria are more probable to be responsible for variations in the severity of influenza 
pandemics. Additionally, the introduction of the pneumococcal vaccine is also believed to 
account for lower numbers of coinfections with S. pneumoniae during the pandemic in 2009 
[35].  
 
 
1.1.2 Treatment and prevention of pneumococcal infections 
 
Treatment 
The treatment of choice of pneumococcal infections is a therapy with antibiotics. Since the 
introduction in the 1940s, penicillin was used against infections with S. pneumoniae. β-
lactam-antibiotics, like penicillin, inhibit the bacterial cell-wall synthesis by interfering with 
penicillin-binding proteins (PBPs). Mutations in several different genes, e.g. pneumococcal 
PBPs or the cell-wall muropeptide branching enzyme MurM, are shown to promote 
resistance development to penicillins [41]. Already in the 1960s, reports about β-lactam-
resistant pneumococci were published [42], and in 2013, Sweden reported that 6.8% of all 
IPD isolates were non-susceptible to penicillins [43]. 
Following the isolation of increasing numbers of penicillin-resistant pneumococci, the use of 
macrolides and fluoroquinolones has become more common to treat respiratory tract 
infections.  Macrolides, like erythromycin or the semi-synthetic azithromycin, inhibit 
bacterial protein synthesis by binding to the 50S ribosomal subunit and inhibit protein 
elongation [44]. Fluoroquinolones, e.g. moxifloxacin, are synthetically produced antibiotics 
that bind to type II topoisomerase enzymes, like DNA gyrase, thereby preventing DNA 
replication and cell division. Macrolide-resistant pneumococci have been isolated in several 
countries with resistance rates up to 80% [45]. In 2013, 6.5% of invasive pneumococci, 
isolated in Sweden, were non-susceptible to macrolides [43]. A study from the same year, 
conducted in the US, reported that about one third of all cases of IPD were caused by 
pneumococci, which were resistant to several antibiotics [46].  
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Prevention  
In order to prevent the spread of antibiotic-resistant pneumococci and the development of 
IPD, a pneumococcal vaccine was introduced. To date, there are 4 different pneumococcal 
vaccines available: A pneumococcal polysaccharide vaccine (PPSV23) and pneumococcal 
conjugate vaccines (PCV7, PCV10 and PCV13), which are shown to protect against the most 
common pneumococcal serotypes linked to IPD (Table 1).  
 
Table 1 Pneumococcal vaccines currently available [47] 
Name Supplier Licensed Serotypes covered 
PPSV23 
Pneumovax®23 Merck 1983 
1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 
14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 
33F 
PCV7 
Prevnar®/ Prevenar® Pfizer 2000 4, 6B, 9V, 14, 18C, 19F, 23F 
PCV10 
SynflorixTM GSK 2009 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F 
PCV13 
Prevenar 13® Pfizer 2010 
1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 
23F 
 
In 1983, a pneumococcal vaccine covering 23 different serotypes was licensed. This vaccine 
is polysaccharide-based and provokes an antibody response against the polysaccharide 
capsule of pneumococci, which promotes opsonophagocytosis. However, polysaccharide-
based vaccines elicit no or only weak immune responses in very young children and adults 
and fail to induce immune memory due to their T-cell independent response (see chapter 
1.2.2) [48].  
In 2000 and 2001, the first PCV was licensed in the US and Europe, respectively [49]. PCVs 
consist of 7, 10 or 13 different capsular polysaccharides, which are coupled to protein 
carriers, a non-toxic variation of the diphtheria toxin, CRM197 (PCV7 and PCV13) or 
protein D from H. influenzae (PCV10). These vaccines cause T-cell dependent immune 
responses and B-cell memory [50]. The introduction of PCVs into national vaccination 
programmes in Europe decreased pneumococcal infections drastically in vaccinated 
individuals, but also in non-vaccinated people because of herd-immunity. In Germany, the 
introduction of PCV7 was recommended from 2006 onwards and led to a vaccine-coverage 
of 84% in 2007. In 2008, Germany reported a 50% reduction in IPD cases in children below 
the age of 2 years [51]. Sweden incorporated PCVs into the national immunization 
programme in 2009. Of all children born in 2013 in Sweden, 96.6% were vaccinated against 
pneumococcal infections by the age of 2 years [52], which led to a considerably reduction of 
IPD cases in vaccinated children [53]. 
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However, although PCVs drastically reduce the nasopharyngeal carriage rates and IPD cases 
caused by pneumococcal serotypes included in the vaccines, other serotypes, not included in 
the vaccine, are found to replace the serotypes in colonization and pneumococcal disease [54, 
55]. In Sweden, 36% of the children between 1 and 5 years were colonized with pneumococci 
before the introduction of pneumococcal vaccines. After the pneumococcal vaccines were 
included into the childhood immunisation programme, the carriage rate was not severely 
different with 30%, which is attributed to serotype replacement [53]. 
In order to produce a vaccine that targets all pneumococcal serotypes simultaneously, several 
studies are concentrating on virulence factors present in all isolates. For example, the 
pneumococcal surface protein A (PspA), the pneumococcal surface antigen A (PsaA), as well 
as pneumolysin have been shown to mediate immunity against pneumococcal infections (See 
chapter 1.3.2) [56-58]. Moreover, immunization experiments with the pneumococcal surface 
protein C (PspC) were also shown to protect against colonization [59]. Increased protection 
rates have been observed, if these antigens were combined in immunization studies [57]. 
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1.2 The immune system 
 
The function of the immune system is to distinguish “self” from “non-self” and evading 
pathogens from non-pathogens, in order to prevent an infection, remove tumour cells and 
maintain an immune homeostasis. The immune system consists of lymphatic organs, physical 
barriers, cells and soluble mediators and can be divided into the innate and the adaptive 
immune response.  
The innate immune system comprises epithelial barriers, e.g. skin and mucosa in the 
respiratory or gastrointestinal tract, cells, like macrophages, neutrophils or dendritic cells 
(DCs), and soluble components, like the complement system and antimicrobial peptides 
(AMPs). It is the first line of defence during an infection, with a rapid and non-specific 
response that is not adapted to the type of pathogen. Moreover, it regulates the adaptive 
immune response, e.g. by producing cytokines. In contrast to the innate immune response, the 
adaptive response is highly specific, adjusted to the pathogen and able to develop an 
immunological memory. Its function is mediated by B- and T-lymphocytes and soluble 
factors, like antibodies. 
 
 
1.2.1 The innate immune response 
 
Detection of invading pathogens and production of inflammatory mediators 
The innate immune system is activated by pathogen-associated molecular patterns (PAMPs), 
structures, which are part of microbial pathogens and are required for their virulence. Usually, 
they are common to many different pathogens. Examples of PAMPs are bacterial DNA and 
lipopolysaccharide (LPS) [60]. PAMPs bind to and activate pattern-recognition receptors 
(PRR) on or inside host cells, e.g. Toll-like receptors (TLRs), nucleotide-binding 
oligomerization domain (NOD)-like receptors (NLRs) or cytosolic DNA receptors.  
To date, we know of 10 human and 13 murine TLRs. While TLR1, TLR2, TLR4, TLR5, 
TLR6 and TLR11 are positioned on the plasma membrane, TLR3, TLR7, TLR8 and TLR9 
are located in endosomes. TLRs consist of an ectodomain, required for the recognition of 
PAMPs, transmembrane domains, and Toll-interleukin 1 (IL-1) receptor (TIR) domains. 
There are different adapter molecules, known to interact with the TIR domain of TLRs, and 
which are required to evoke a response by the host cell. All TLRs, except for TLR3, known 
to recognize double-stranded ribonucleic acid (dsRNA), use the myeloid differentiation factor 
88 (MyD88) as an adapter molecule to induce the transcription of inflammatory cytokines by 
activating the transcription factor nuclear factor-kappa B (NF-κB) and mitogen-activated 
protein kinases (MAPKs). TLR3, and also TLR4, use a TIR-domain-containing adapter 
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protein-inducing interferon-β (TRIF) as an adapter molecule to stimulate the transcription 
factors interferon regulatory factor 3 (IRF-3) and NF-κB, leading to the induction of type I 
interferon (IFN) and inflammatory cytokines, like interleukin-6 (IL-6) or tumor necrosis 
factor α (TNFα) [61, 62]. 
NLRs are located in the cytoplasm of cells. To date, we know of at least 22 different types in 
humans, and 33 in mice. NLRs consist of C-terminal leucine-rich repeats that recognize 
PAMPs, a nucleotide-binding oligomerization domain (NOD) and a variable N-terminal 
protein-protein interaction domain, e.g. caspase recruitment domain (CARD), that is crucial 
for inducing downstream signals, like NF-κB activation, leading to the transcription of pro-
inflammatory cytokines [63]. Inflammasomes, consisting of nod-like receptor protein 3 
(NLRP3) and absent in melanoma 2 (AIM2), are intracellular protein complexes that are 
activated upon bacterial infections. They recruit apoptosis-associated speck-like protein 
containing CARD (ASC), which binds to caspase-1 and evokes cleavage of the pro-forms of 
IL-1β and IL-18, thus leading to their maturation [62, 64]. 
 
 
Figure 3 Schematic representations of selected PRRs and their known pneumococcal PAMPs. 
Pneumococcal LTA is sensed by TLR2, while TLR4 has been proposed to recognize Ply. The 
endosomal TLR9 senses DNA. TLRs that use MyD88 as an adapter (TLR2, TLR4, TLR9) induce the 
transcription of inflammatory cytokines, TLR3 and TLR4 signal via TRIF and thus activate 
additionally the expression of type I IFN. Ply is able to activate the NLRP3/AIM2 inflammasome and 
hence leads to the production of IL-1β. PGN activates NOD2 and the transcription of inflammatory 
cytokines, while DNA that signals via STING additionally induces type I IFN. 
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Various pneumococcal structures can be sensed by PRRs. Lipoteichoic acid (LTA), a 
component of the pneumococcal cell wall, is sensed by TLR2 [65]. Unmethylated CpG 
motifs in pneumococcal DNA can be recognized by TLR9 [66], and the pneumococcal toxin 
pneumolysin (Ply) has been suggested to be sensed by TLR4 [67]. Peptidoglycan (PGN), 
another pneumococcal cell wall component, can be sensed by NOD2, dependently on the 
activity of the pneumococcal toxin pneumolysin [68, 69]. Moreover, pneumolysin is capable 
of activating the inflammasome and subsequent production of IL-1β and IL-18 [70, 71] and is 
also required for the pneumococcal activation of the cytosolic DNA receptor stimulator of 
interferon genes (STING) [72] (Figure 3). 
 
Macrophages 
Bone marrow-derived monocytes, which circulate in the blood, are recruited and differentiate 
into macrophages and DCs during an inflammation [73]. Macrophages play a central role in 
the immune response and are present in many tissues and organs, especially those, which are 
exposed to the environment [74]. In the lungs, residential alveolar macrophages (AMs) 
represent 95% of all cells, and are therefore the major cell type [75]. 
The key function of macrophages is the phagocytosis and killing of particles and pathogens, 
both opsonized and non-opsonized [75, 76]. Invading microbes can be recognized and taken 
up into the cell due to binding to different receptors on the cell surface, like C-type lectins 
(e.g. mannose receptor), scavenger receptors (e.g. macrophage receptor with collagenous 
structure (MARCO)), complement receptors (CR) or immunoglobulin receptors (Fcγ 
receptors) [77, 78]. 
Following phagocytosis, pathogens are eradicated by reactive oxygen species (ROS) or 
reactive nitrogen species (RNS), e.g. superoxide, hydrogen peroxide (H2O2) or nitric oxide 
[79]. Furthermore, host cells secrete pro-inflammatory cytokines and chemokines, like IL-8, 
which recruit neutrophils to the site of infection, and the production of monocyte 
chemoattractant protein-1 (MCP-1) or RANTES evokes an influx of activated monocytes and 
lymphocytes [75].  
Macrophages play a significant role in fighting pneumococcal pneumonia and the importance 
of several receptors in pneumococcal uptake has been described in the literature. Scavenger 
receptors, such as MARCO [80], C-type lectins, such as SIGN-R1 [81], or the complement 
receptor CR3 [82] have been shown to mediate pneumococcal phagocytosis. Pneumococci, 
on the other hand, evade phagocytosis mechanisms by the host with the help of their thick 
polysaccharide capsule [83]. Although the production of ROS has been implicated in 
macrophage-mediated killing of different bacteria, pneumococcal clearance by macrophages 
is facilitated by RNS, and not attributed to ROS production [84].  
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Neutrophils 
Neutrophils are produced in the bone marrow and are afterwards released into the vascular 
system, where they represent 60% of all leukocytes in humans [85]. During inflammation in 
the lungs, macrophages and epithelial cells produce cytokines and chemokines, which recruit 
neutrophils into the alveolar space [86, 87]. Like macrophages, neutrophils phagocytose 
bacteria and eradicate them with the help of ROS, but also non-oxidative mechanisms, like 
AMPs, proteases and the formation of neutrophil extracellular traps (NETs) [88, 89].  
As mentioned above, S. pneumoniae was shown to avoid phagocytosis and to be resistant to 
ROS. Instead, neutrophils fight pneumococcal infections with serine proteases [90, 91]. In 
order to escape killing by neutrophils, pneumococci have developed different immune 
evasion strategies. The pneumococcal capsule was shown to promote escape from NETs [92], 
and pneumococcal endonuclease A degrades DNA, the main building block of NETs [93]. 
 
Dendritic cells 
DCs account for only 1% of all immune cells [94].  They originate in the bone marrow, and 
represent the connection between the innate and the adaptive immune response. These cells 
express a number of receptors, like scavenger, complement receptors or Fc receptors, which 
promote phagocytosis and are thus required for antigen presentation, the most important 
function of DCs [95]. 
DCs are located in the mucosa, where they constantly collect antigens. After maturation and 
translocation to the lymph nodes, they present these antigens to T-cells via major 
histocompatibility complex class II (MHC class II) molecules, leading to the activation of T-
cells and the initiation of an adaptive immune response [96].  
 
Antimicrobial peptides and collectins 
AMPs are effective against Gram-positive and Gram-negative bacterial, viral, as well as 
fungal pathogens and show a great variation in size (6 - 59 amino acids), sequence and 
secondary structure. They bind to microbes and kill them either by disturbing membrane 
integrity and causing lysis, or they enter the cell and interfere with essential mechanisms, e.g. 
nucleic acid synthesis [97].  
In the respiratory tract of humans, primarily epithelial cells and neutrophils produce AMPs, 
which help to kill invading pathogens [98]. Neutrophil α-defensins / human neutrophil 
peptides (HNPs), human β-defensins (hBDs), and cathelicidins, like hCAP18/LL-37 are the 
major AMPs present in the lungs and bronchoalveolar lavage (BAL) (see Table 2) [99].  
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Table 2 AMP-producing cells in the respiratory tract of humans [99, 100] 
Cell type AMPs Function 
Neutrophils α-defensins (HNP 1-4) Microbial killing 
Epithelial cells hBDs 
Microbial killing 
Chemo-attraction of immune cells 
Activation of DCs 
Neutrophils 
Epithelial cells 
hCAP18/LL-37 Microbial killing 
 
 
Some hBDs, like hBD-1, are constitutively expressed, while other hBDs are induced e.g. by 
TLR-signalling or cytokine expression [100]. LL-37 is shown to be resistant against 
proteolytic activity due to its ability to form aggregates [101]. Its expression is regulated by 
inflammatory signalling, Vitamin D and endoplasmic reticulum stress. The murine 
homologue of LL-37 cathelicidin-related antimicrobial peptide (CRAMP) [102] and several 
defensins have been identified in mice [103], which are suggested to play an important role in 
murine host defence mechanisms in the lung [104].  
Pneumococci are sensitive to treatment with LL-37 from mast cells [105] and human α-
defensins produced by neutrophils [106]. Furthermore, primary human lung epithelial cells 
have been shown to secrete hBD-2 and hBD-3 in response to pneumococcal infections, which 
promoted bacterial clearance [107].  
In the lungs, surfactants are secreted by type II alveolar epithelial and Clara cells [108] and 
consist of 90% lipids and 10% proteins. They play an important role in reducing surface 
tension, and take part in the innate immune response. There are several surfactant proteins 
(SP). This thesis includes SP-A and SP-D, which are hydrophilic and belong to the group of 
collagen-containing C-type lectins (carbohydrate-binding proteins), so-called collectins. SP-A 
is believed to stabilize surfactants, while SP-D is involved in keeping the homeostasis. 
Moreover, both proteins opsonize pathogens, promoting their clearance [109, 110].  
Recombinant SP-D was found to bind to and agglutinate pneumococci, but did not promote 
neutrophil-mediated killing [111]. Using an in vivo model of intranasal challenge, it was 
demonstrated that SP-D endorses pneumococcal clearance and prevents bacterial 
translocation from the upper to the lower respiratory tract [112]. SP-A, on the other hand, was 
shown to promote pneumococcal uptake by alveolar macrophages via the scavenger receptor 
[113]. 
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1.2.2 The adaptive immune response 
 
T-lymphocytes 
Naïve T-lymphocytes (or T-cells) originate in the thymus and are found in the blood and 
lymphatic organs. T-cell receptors on their surface recognize antigens which are presented via 
MHC molecules, e.g. by DCs. This leads to the activation of the T-cells, evoking either a 
cytotoxic function or the production of cytokines. Cytotoxic T-cells (or CD8+ T cells) are 
activated by MHC class I molecules and have the ability to directly kill infected cells, e.g. by 
lysis. CD4+ helper T-cells, on the other hand, are activated by MHC class II molecules and 
produce cytokines, which can be lethal to infected cells, and lead to immunoglobulin (Ig) 
production by B-cells or stimulate other T-cell functions [114]. 
After an infection with S. pneumoniae, DCs produce large amounts of IL-12, a pro-
inflammatory cytokine that promotes the differentiation of helper T-cells (TH-cells). Several 
studies have elucidated the importance of IFN-γ secretion by TH-1 cells in in vivo models 
after pneumococcal challenge [115-117]. 
 
B-lymphocytes 
B-lymphocytes (or B-cells) mature in the bone marrow and play a major role in the adaptive 
immune response. B-cells bind and take up antigens, in order to present them on their surface 
by MHC class II molecules. These antigens can now be recognized by specific TH-cells, 
which in turn stimulate the differentiation of B-cells into plasma cells producing high-affinity 
class-switched antibodies (IgG, IgE or IgA) or memory B-cells [118, 119]. 
Carbohydrates alone, like the pneumococcal vaccine PPSV23, activate B-cells in a T-cell 
independent manner, since they cannot be presented by MHC class II. Therefore, B-cells are 
only capable of producing short-lived low-affinity antibodies, like IgM.  Subsequently, the 
immune response does not last long. Furthermore, children under the age of 2 years are not 
able to evoke an immune response to carbohydrates only, since their B-cells are not fully 
matured. They hardly express type 2 complement receptors and lack certain cytokines, 
needed to activate B-cells. In order to induce an immune response in very young children, the 
pneumococcal vaccines PCV7, PCV10 and PCV13 were designed differently. The 
pneumococcal polysaccharides have been linked to a carrier protein, which can be presented 
by MHC class II molecules and this leads to a T-cell dependent immune response [118].  
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1.3 Pneumococcal-Host interactions 
 
Carbohydrates are essential structures to enable pneumococcal interactions with the host. 
They facilitate pneumococcal colonization and invasive disease but also evoke a host immune 
response. The following chapter will discuss host glycosylation, with an emphasis on sialic 
acids (Sias), the carbohydrates that are found on the tip of most glycan strands. In order to 
hide and escape from the host’s immune system, pneumococci comprise several virulence 
factors, of which the pneumococcal capsule, the sialidase NanA, the main Sia transporter 
SatABC, the two-component system CiaRH, the streptococcal pyruvate oxidase SpxB, the 
serine protease HtrA, and pneumolysin will be described. Moreover, the pathogenesis of 
influenza/pneumococcal coinfections will be discussed. 
 
 
1.3.1 Host glycans and their biological functions 
 
Host glycosylation 
In 1967, Rambourg and colleagues observed that the cell surface is highly covered with sugar 
molecules, the glycocalyx [120]. Glycans exist in many variations and are built of mono- or 
oligosaccharides, which are covalently linked to a non-carbohydrate moiety, a protein or 
lipid, or exist freely [121]. The most common monosaccharides present in mammalian 
glycoconjugates are listed in Table 3.  
 
Table 3 The most common monosaccharides in mammalian glycans [121] 
Name Structure Examples 
Sialic acids  Nine-carbon backbone acidic sugar N-acetylneuraminic acid, N-glycolylneuraminic acid  
Hexoses Six-carbon neutral sugars Glucose, galactose, mannose 
Hexosamines Amino group at position 2 of an hexose which is free or N-acetylated 
N-acetylglucosamine, N-acetyl-
galactosamine  
Deoxyhexoses Six-carbon neutral sugar without hydroxylgroup at position 6 Fucose  
Pentoses Five-carbon sugar Xylose  
Uronic acids Hexose with negatively charged carboxylate at position 6 Glucuronic acid, Iduronic acid  
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Glycosylation is the most common post-translational modification of proteins. Depending on 
their linkage to a protein, the aglycone, glycans are mainly divided in to N- and O-linked. N-
linked glycans are covalently attached to a polypeptide via an asparagine (Asn) residue. O-
linked glycans are linked to the polypeptide via N-acetylgalactosamine (GalNAc) on a serine 
(Ser) or threonine (Thr) residue (Figure 4). In eukaryotes, these glycosylations take place in 
the cytoplasm, the endoplasmatic reticulum and golgi [121, 122].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Schematic representations of common mammalian glycans. Glycoproteins and 
glycolipids are usually decorated with chains of GalNAc, galactose (Gal), N-acetylglucosamine 
(GlcNAc), mannose (Man), fucose (Fuc) or glucose (Glc) molecules, with a terminal Sia molecule. 
Modified after Varki (2007) [123]. 
 
Other life forms such as plants and bacteria differ greatly from mammals in their 
oligosaccharide composition. To date, several glycans are exclusively found in bacteria, e.g. 
3-deoxy-D-manno-oct-2-ulosonic acid (KDO), presenting part of the core of the bacterial 
endotoxin LPS, and N-acetylmuramic acid (MurNAc), found in peptidoglycan, the main 
building block of the bacterial cell wall [124]. 
 
Sialic acids 
The biochemists Blix and Klenk discovered Sias in glycolipids of the brain and in salivary 
mucins [125, 126]. The terminal monosaccharide of glycoconjugates, like glycoproteins and 
glycolipids, is usually a nine-carbon backbone sugar, called neuraminic acid or Sia, with 
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modifications mainly occurring at position 4, 5, 7, 8 and 9 [121, 127]. Sias are found on all 
cells in animals of the deuterostome lineage (from sea urchins to mammals) [123, 128], and 
in some bacteria, fungi and protozoa [129]. Although Sias are usually not present in insects, 
they have been detected in early developmental stages of Drosophila melanogaster and the 
cicada Philaenus spumarius [130, 131]. 
To date, there are about 50 different types of Sia known in nature. Neu5Ac (N-
acetylneuraminic acid) and Neu5Gc (N-glycolylneuraminic acid) are the most common ones 
[128]. Most of them are attached by their 2-carbon to the 3- or 6-carbon of Gal or GalNAc 
underneath, commonly referred to as α2-3- or α2-6-linkage [121].  
 
CMP-NeuAc hydroxylase (CMAH) 
In most animals, the enzyme CMP-Neu5Ac hydroxylase (CMAH) transforms CMP-Neu5Ac 
into CMP-Neu5Gc by adding a single oxygen atom [132]. About 3 million years ago, a 92-bp 
deletion in the exon 6 encoding CMAH occurred in humans. Consequently, humans are only 
able to synthesize Neu5Ac, while many other mammals, including our closest relatives the 
chimpanzees, present mainly Neu5Gc as terminal sugar on their glycoconjugates (Figure 5) 
[133, 134]. The occurrence of the CMAH mutation was predicted to have happened when 
stone tools were used to butcher hunted animals, which might have caused minor injuries and 
infections [135]. It was suggested that evolutionary pressure caused by Neu5Gc-recognizing 
pathogens and higher fertility of Neu5Gc-negative females led to the positive selection of 
CMAH-negative individuals [136, 137]. 
 
Noteworthy, humans are not the only species with a non-functional CMAH. Recently, it was 
described that New World Monkeys obtained a mutation in their CMAH gene already 30 
million years ago [138]. Likewise, ferrets have a mutation in CMAH in their genome, which 
was shown to increase their susceptibility to human IAV [139].  
 
Different human-adapted pathogens have evolved their virulence mechanisms in accordance 
to the human Sia profile. The merozoit of Plasmodium falciparum recognizes Neu5Ac, but 
not Neu5Gc [140], therefore infecting New World monkeys but no other primates [141]. 
Similarly, the typhoid toxin of Salmonella Typhi was shown to strongly bind to Neu5Ac, but 
only weakly to Neu5Gc [142].  
 
The loss of Neu5Gc is shown to affect B-cell reactivity in Cmah-/- mice, since its absence 
leads to enhanced levels of B-cell proliferation and antibody production [143]. Similarly, T-
cells of Cmah-/- mice exhibit a greater activation upon stimulation compared to wt cells, 
which can be repressed by Neu5Gc-treatment [144]. Moreover, in comparison to 
chimpanzees, humans display a more active immune system. Both B- and T-lymphocytes of 
humans are reported to react stronger to stimuli than those of chimpanzees [145].  
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Although humans are not able to synthetize Neu5Gc, this Sia can be incorporated into human 
tissues through their diet. Neu5Gc is antigenic in humans, evoking an antibody response 
[146], which was suggested by Hedlund et al. to promote inflammation and the development 
of cancer [147] and later experimentally confirmed by Samraj et al. using Cmah-/- mice [148]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Humans have a deletion in the gene encoding CMAH. Due to the inactive CMAH, human 
cells only produce Neu5Ac. Most other mammals, including non-human hominids like gorillas or 
chimpanzees, convert Neu5Ac into Neu5Gc. Both molecules differ in a single oxygen atom (framed).  
 
 
Role of glycosylation in the host  
The majority of glycans are indispensible in biological systems and their roles are very 
divers. Therefore, this chapter only highlights some of the most important features.   
Glycans define the physical characteristics of many structures, like plant cell walls or 
exoskeletons of insects [149, 150]. Moreover, glycosylation is required for correct folding of 
glycoproteins [151], and to protect them from cleavage by proteases [152]. Sias are 
fundamentally important for embryonic development, as the disruption of their biosynthesis 
is lethal in a mouse model [153]. Negatively charged Sias on the cell surfaces lead to the 
electrostatic repulsion and thus prevent non-specific interactions of cells, e.g. of red blood 
cells in circulation [154]. In addition, they are important for cell-cell interactions, like the 
binding of P-selectins (Calcium-dependent lectins) on endothelial cells and glycoproteins on 
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the surface of neutrophils, which enables neutrophil adhesion to endothelial cells and their 
“rolling" as part of inflammatory processes [155]. 
 
The most important function of glycans, e.g. Sias, is probably to distinguish ‘self’ from ‘non-
self’. By covering receptors and antigenic proteins, glycans are recognized as self-associated 
molecular patterns (SAMPs), which prevent immune responses against host-derived 
structures [156]. Several members of the family of CD33-related Sia recognizing 
immunoglobulin superfamily lectins (CD33r Siglecs) have been shown to be involved in 
the prevention of immune responses. CD33rSiglecs are transmembrane receptors that 
consist of extracellular sialic-acid binding domains, immunoglobulin domains and often of 
at least one cytosolic immune-receptor tyrosine-based inhibitory motif (ITIM), which 
inhibit cell activation and cytokine signalling when the ligand is bound [157].  
In contrast, asialoglycoproteins, desialylated structures, are recognized by the hepatic 
Ashwell-Morell receptor, which removes them from circulation [158]. This is of importance 
in the clearance of e.g. senescent platelets. These blood components take part in coagulation 
and regulate their own elimination with the help of neuraminidases, which desialylate their 
surface-located glycan structures in order to evoke their clearance [159].  
 
Role of glycans during infection 
Many pathogens enter the host via inhalation into the respiratory tract and encounter 
epithelial surfaces, which are usually covered by a thick and viscous layer, consisting of high 
molecular weight glycoproteins with many clustered O-linked glycans, the so-called mucins, 
water, salts, lipids and other highly glycosylated proteins [160, 161]. The mucus traps 
microbes and particles, which are cleared by cilia movement or coughing [162]. Thus the 
mucus presents a physical barrier to inhibit invading pathogens.  
 
However, infections and inflammations have been shown to alter glycosylation of the host. 
One example is the sialylated LewisX blood group antigen. It plays an important role 
during inflammation [163], as it is upregulated in gastric tissues during Helicobacter pylori 
infections [164], as well as in the respiratory mucins of cystic fibrosis patients [165].  
Microbes interact with glycans on the surface of host cells, which promotes pathogenesis 
[166]. During pneumococcal colonization, adhesion to glycosaminoconjugates, like heparan 
sulfate, presents one of the first steps in the interaction with epithelial cells [167]. 
Furthermore, pneumococci engage with the host glycocalyx and produce enzymes and 
transporters to scavenge and take up Sias (see chapter 1.3.2), but also other sugars, like Gal 
and GlcNAc, of the glycan strand [168, 169]. In pneumococci, Sia has been shown to 
promote biofilm formation, nasopharyngeal colonization and bacterial outgrowth from the 
upper to the lower respiratory tract [170-172]. While intranasal administration of Neu5Ac 
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enhanced pneumococcal colonization and spread to the lungs and brain of mice, Neu5Gc did 
not have any effect on pneumococcal carriage or disease [170, 173]. 
Viruses, like IAV, also interact with Sias on host cells in order to facilitate their entry [35]. 
Human IAV adheres preferentially to α2-6-linked Sias [174], which are present on ciliated 
cells in the respiratory tract [175]. 
Interestingly, bacteria have developed strategies to evade the host’s immune response by 
mimicking host glycans or by decorating themselves with Sias. While some bacteria are able 
to synthesize Sia on their own (e.g. Escherichia coli K1 or N. meningitidis), others, like N. 
gonorrhoeae, scavenge Sias from host substances and sialylate their surfaces with the help of 
sialyltransferases [129].  
 
The capsule of group B streptococci (GBS) is shown to contain Sias and represents a major 
virulence factor [176]. By binding to the CD33r Siglec-9 on neutrophils, the capsular Sia of 
GBS downregulates its own killing [177]. In contrast, the pneumococcal capsule does not 
contain Sias, but pneumococci express sialidases, which cleave terminal Sias from the glycan 
strand [178].  The pneumococcal sialidase NanA has been associated with an unmasking of 
the CD33r Siglec-5 and subsequent induction of an immune response in macrophages [179]. 
During sepsis, NanA removes terminal Sias from glycoconjugates of platelets, promoting 
intravascular coagulation. The Ashwell receptor clears desialylated platelets from the 
circulation and therefore improves the outcome of this complication [180]. 
As discussed earlier, PRRs, e.g. TLRs or NLRs recognize PAMPs. Such ligands are often 
glycan-containing structures, e.g. bacterial LPS or peptidoglycan, or nucleic acids, like 
bacterial and viral DNA or RNA [181], which play a significant role in host-microbe 
interactions. 
 
Sialic acid catabolism in bacteria 
Since glucose is not detectable in the respiratory tract of healthy individuals [182], pulmonary 
pathogens may utilize Sia in order to gain energy in form of nitrogen or carbon [183]. Studies 
in E. coli have shown that Neu5Ac is transported into the bacterial cell and catabolized, 
leading to the generation of pyruvate and N-Acetylmannoseamine (ManNAc), which is, via 
several steps, converted to Fructose-6-Phosphate, which is part of the glycolysis [184, 185]. 
Moreover, it was shown that E. coli is also able to grow on Neu5Gc as sole carbon source by 
using the same enzymes as for the catabolism of Neu5Ac [186]. 
 
S. pneumoniae was predicted to possess all genes required for Sia metabolism [187, 188]. 
However, in contrast to TIGR4, D39 is not able to ferment Sia due to a frameshift in the gene 
for the neuraminate lyase [168]. 
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Other serotypes, like 19F and 23F, are shown to be able to grow on Sia Neu5Ac as sole 
carbon source. As compared to the presence of glucose, growth on ManNAc or Neu5Ac only 
leads to a much prolonged generation time [168, 172, 189].  
 
 
 
1.3.2 Pneumococcal virulence factors 
 
Capsule 
Pneumococci are surrounded by a thick polysaccharide capsule, which presents a major 
virulence factor and is the target for current vaccines on the market [4]. Non-encapsulated 
isolates seldom cause IPD in humans [190] and are significantly attenuated in their virulence 
using mouse models [191]. The composition of the capsule varies greatly between serotypes 
[4], and affects the invasive disease potential of the bacteria, although other bacterial factors 
are also involved [192]. Since most capsular types are negatively charged, electrostatic 
repulsion prevents pneumococci from being trapped in the mucus and from phagocytosis by 
immune cells [83]. Moreover, the capsule shields surface proteins and protects pneumococci 
from recognition and opsonisation by immune cells [193].  
Pneumococci of the same serotype can show substantial variations in their capsular thickness, 
and are therefore divided into opaque and transparent variants. The switch in capsule 
production, also known as phase variation, allows pneumococci to adapt to different body 
sites, like the mucosa of the respiratory tract or the blood stream. In contact with epithelial 
cells, pneumococci produce lower amounts of capsular polysaccharide in order to expose 
adhesive structures on their surface [194]. These transparent variants were shown to establish 
a robust colonization in an infant-rat model [195], but hardly caused any sepsis in a mouse 
model after intraperitoneal challenge. In contrast, all mice succumbed to an intraperitoneal 
infection with opaque isolates, which produce large amounts of capsule and reduce the 
detection by the immune system [196]. 
 
Virulence factors involved in sialic acid scavenging and uptake  
S. pneumoniae is able to use Sia as carbon source [172, 197].  Genes for Sia removal, uptake 
and metabolism are encoded in two loci, the nanAB and nanC loci [178, 184]. These genetic 
regions harbour up to three different sialidases, with NanA, NanB and NanC to be common 
to 100%, 96% and 51% of all isolates, respectively [198]. 
 
The nanAB locus is predicted to contain four transcriptional units [178] and catabolite 
repression elements, which lead to its transcriptional inhibition in the presence of glucose 
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[199]. In the absence of glucose, genes within this locus are upregulated in response to 
Neu5Ac [189, 200].  
 
This thesis focuses on NanA, which is a typical sialidase and scavenges Sias from host 
glycoconjugates [169, 201]. NanA is located on the bacterial surface and linked to the 
peptidoglycan cell wall via an LPxTG motif in most pneumococci [202]. Interestingly, in S. 
pneumoniae TIGR4 NanA is secreted due to an authentic frameshift [188].  
Despite comprising an enzymatic active part, NanA also consists of a carbohydrate-binding 
domain. Using a model of experimental meningitis, it was demonstrated that the lectin-like 
domain is of higher importance than the sialidase domain to achieve adhesion to and invasion 
into brain endothelial cells, as well as to activate an immune response in these cells [203, 
204]. 
 
NanA is able to remove both α2-3- and α2-6-linked Sias from the underlying Gal of the 
glycan strand [178]. By removing terminal Sias from epithelial cells, potential binding sites 
are unmasked, and pneumococcal adhesion is promoted [205]. Additionally, desialylation of 
THP-1 monocytes is reported to stimulate an immune response and to induce cytokine 
secretion [179]. Moreover, it was suggested that desialylation of host factors, e.g. lactoferrin, 
interferes with their functionality [178], thus promoting pneumococcal immune evasion.  S. 
pneumoniae has also been demonstrated to desialylate host structures of other bacteria in the 
respiratory tract, like N. meningitidis and H. influenzae, which is proposed to provide a 
competitive advantage for pneumococci [206]. 
NanA expression is increased in transparent compared to opaque variants [178], and it was 
shown to be beneficial during colonization in a chinchilla model [201]. Moreover, nanA 
transcription was strongly increased in bacteria isolated from the nasopharynx, lungs and 
brain of mice in comparison to blood [207, 208].  
Several groups observed that NanA is also required for colonization of the nasopharynx and 
lungs using a murine model of intranasal challenge [209, 210]. Moreover, a recent study 
reported that NanA-mediated exposure of Gal in vivo in the nasopharynx promotes 
pneumococcal biofilm formation [211]. During sepsis, NanA is demonstrated to be redundant 
for pneumococcal survival in the vascular system [210, 212, 213], but there are studies 
showing a reduced virulence of NanA-deficient mutants in the blood stream [209, 213]. 
Moreover, NanA has been shown to promote pneumococcal meningitis in murine in vivo 
models [203]. 
 
Three different Sia transporters have been predicted in the nanAB and nanC loci of S. 
pneumoniae TIGR4, a solute symporter SP1328, and two ABC transporters SP1688-90 and 
SP1681-83 [187]. The latter was identified as the main Sia transporter, and named SatABC, 
Moreover, it has been shown to play an important role in nasopharyngeal colonization of 
mice [172].  
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Two-component system CiaRH  
Two-component systems (TCS) allow bacteria to sense and respond to environmental signals. 
They comprise a membrane-bound histidine kinase (HK), and a cytoplasmic response 
regulator (RR). The HK detects the signal on the outside of the cell, is autophosphorylated 
and phosphorylates the RR, which alters its conformation in order to bind to specific 
promoter regions and thus regulates transcription [214].  
 
In S. pneumoniae, 13 different TCS and a single RR have been annotated, of which the 
majority affects pneumococcal virulence [215]. During the analysis of mutants resistant to the 
β-lactam antibiotic cefotaxime, TCS05, also known as CiaRH, was identified and a 
connection with the pneumococcal cell wall machinery was suggested [216]. Besides 
sensitivity to cefotaxime, CiaRH was also shown to affect autolysis. Deletion mutants in ciaR 
lyse quickly upon entry into stationary phase or in response to cell wall inhibitors, like 
vancomycin [217]. Other studies revealed that CiaR regulates the expression of several genes 
involved in biosynthesis of the pneumococcal cell wall [218, 219]. 
 
The use of microarrays and solid-phase DNA binding assays also identified the high-
temperature requirement A gene (htrA) to be regulated by CiaRH [218, 219] (see below), and 
the contribution of CiaRH to oxidative stress resistance and virulence in rodents, using 
nasopharyngeal colonization and pneumonia models, was demonstrated [215, 219, 220]. 
Moreover, CiaRH was shown to play a role in bacteriocin production [218]. 
A mutation in the HK CiaH that mimicked its activation, led to the complete abolishment of 
competence [216], while a mutation in RR CiaR restored competence [221]. Another study 
reported the upregulation of the competence operon in a ciaRH-mutant [219]. However, a 
direct interaction between CiaR and genes involved in competence could not be observed 
[218]. Moreover, CiaR expression is also regulated by competence, as ciaR transcription is 
increased in the late phase of competence, which was suggested to promote re-entry into the 
non-competent state [222]. 
 
The external stimulus for the activation of CiaH is not known yet, but it might be induced 
upon stress. Alignments of promoter sequences targeted by CiaR identified its binding motif 
(NTTAAG-N5-TTTAAG) [223]. Moreover, by cloning CiaR-regulated promoter regions in 
front of a β-galactosidase gene (lacZ), it was shown that the position of the binding motif 
affects transcription control. If the motif is located upstream of the transcriptional start site, 
CiaR will positively regulate gene transcription. In contrast, if the binding site is located on 
the other DNA strand inside the transcribed region, CiaR downregulates promoter activity 
[224].  
Bioinformatic analysis identified five cia-regulated small RNAs (csRNA). Their functional 
analysis implicated a role in autolysis, although the phenotype that was caused by their 
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deletion was not as pronounced as in a ciaR null mutant [224]. Moreover, a function in 
competence [225, 226] and virulence in mice after intranasal challenge was suggested [227]. 
 
CiaRH is conserved in streptococci but absent in other bacterial species [223]. In order to 
bind to promoter fragments and to regulate transcription, CiaR needs to be phosphorylated. 
Interestingly, depending on the growth media used, CiaH is or is not required to activate CiaR 
[221, 228]. Intracellular acetyl phosphate (AcPh) production is strongly regulated by the 
streptococcal pyruvate oxidase (SpxB) (see below) [229]. Deletion of SpxB leads to a 
significant downregulation of CiaR-regulated genes, suggesting that intracellular AcPh is 
capable of phosphorylating this RR [230]. 
 
Streptococcal pyruvate oxidase (SpxB) 
The pneumococcal pyruvate oxidase SpxB is located in the cytoplasm and catabolizes the 
decarboxylation of pyruvate leading to the production of AcPh and H2O2 [231]. Pneumococci 
generate high concentrations of H2O2, which enables them to outcompete other respiratory 
pathogens, like N. meningitidis or H. influenzae, present in the same niche [232]. 
Interestingly, pneumococci themselves lack catalase [233]. Instead HtrA, as mentioned 
above, was shown to promote resistance to oxidative stress [234]. 
 
SpxB has been associated with the pneumococcal capability to bind to glycoconjugates, 
which are found on endothelial cells and lung epithelial cells [231]. A mutation in spxB leads 
to drastically reduced AcPh and acetyl-CoA amounts in the bacteria, which are suggested to 
mediate adhesin expression. On one hand, acetyl-CoA is required for the biosynthesis of fatty 
acids, amino acids and the cell wall, and subsequently affects fundamental structures of the 
bacterial cell [231]. On the other hand, AcPh is known to act as a phospho-donor for bacterial 
TCS [235]. A deletion of spxB downregulates ciaR mRNA levels and thus CiaR- regulated 
genes [230], which might affect adhesin expression. 
H2O2 has been shown to inhibit ciliary beating and cell integrity of human nasal epithelial 
cells [236]. It was also reported to induce host cell apoptosis in meningitis models, using 
microglia cells and rat primary neurons [237], and in lung epithelial cells by introducing 
DNA double-strand breaks [238]. It has been reported to evoke stress responses in respiratory 
epithelial cells and the secretion of inflammatory mediators [239]. Moreover, a deletion of 
spxB in serotype 4 pneumococci reduces the production of capsular polysaccharides [240]. In 
summary, SpxB is a main pneumococcal virulence factor and its importance has been 
demonstrated using several in vivo models, e.g. of colonization, pneumonia or bacteraemia 
[231, 240]. 
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High temperature requirement A (HtrA) 
HtrA is a serine protease that is highly conserved among bacteria and located on the 
pneumococcal surface [241]. It plays an important role in protein quality control, as it is 
described to have chaperone and protease functions. HtrA promotes protein folding at lower 
temperatures, and fosters degradation of misfolded proteins at higher temperatures [242].  
 
In pneumococci, HtrA promotes growth at higher temperatures [234] and its expression is 
regulated by the pneumococcal TCS CiaRH [218, 219]. Moreover, HtrA mediates 
pneumococcal resistance to oxidative stress [234], which is caused by ROS-producing 
immune cells like macrophages or neutrophils [243, 244]. 
Several reports have highlighted an effect on competence by HtrA, although they presented 
opposing results. Some studies have shown that HtrA contributes to the inhibitory effect of 
CiaRH on competence by degrading competence-stimulating peptides [241, 245], while 
others have demonstrated a decrease in competence in a mutant lacking HtrA [234]. 
HtrA of H. pylori and Campylobacter jejuni have been shown to degrade E-cadherin, which 
leads to the disruption of tight junctions, promoting bacterial invasion [246, 247]. In S. 
pneumoniae, HtrA has also been associated with virulence. Mutants in htrA showed lower 
colonization rates and led to lower bacterial counts in the lungs of rodents after an 
intranasal challenge, as well as a reduced rate of bacteraemia after intravenous infection 
[219, 234, 248]. 
 
Pneumolysin  
Pneumococci were the first bacteria, which were demonstrated to lyse red blood cells [249]. 
This lysis is caused by pneumolysin, a major virulence factor, which is expressed by nearly 
all pneumococcal isolates [250]. It is a 52 kDa binding monomer that forms a ring of 30-50 
subunits, thus interfering with membrane integrity and leading to cell lysis [251, 252].   
 
Pneumolysin binds to cell membranes via cholesterol [251], but has also been reported to 
adhere to glycan structures. It was shown to attach to mannose and sialylated LewisX blood 
group antigens on the cell surface, since the haemolytic activity of pneumolysin was 
strongly inhibited after pre-incubation with these sugars [253, 254]. Sialyl LewisX is found 
on various immune cells like neutrophils or monocytes [255, 256] and has been shown to 
play a significant role in the first step of extravasation of these cells [163]. 
 
To interact with host cells, pneumolysin has to be present on the outside of bacteria. 
Interestingly, pneumolysin was found to be located in the cytoplasm [257] and does not 
contain a signal sequence, which would direct its translocation to the extracellular space 
[258]. Yet, it is detected non-covalently attached to the bacterial cell wall [259]. For many 
years, pneumolysin was thought to be released during pneumococcal autolysis. However, 
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recent studies demonstrated an autolysis-independent secretion of the cytotoxin, suggesting 
an active transport of pneumolysin out of the bacterial cell [260-262].  
 
Pneumolysin activates the immune system. It promotes bacterial adhesion to epithelial cells 
[263] and reduces ciliary movement in the lungs [236]. At sublytical concentrations, 
pneumolysin stimulates the secretion of cytokines, like IL-6, TNFα or IL-1β, by different 
cell types, e.g. DCs and monocytes [71, 264]. However, other reports showed an inhibition of 
inflammatory responses by pneumolysin [265, 266]. While some studies demonstrated that 
host cells sense pneumolysin in a TLR4-mediated way, others observed TLR4-independent 
but inflammasome dependent signalling in response to this cytotoxin [71, 267]. Its 
importance in vivo was demonstrated using mouse models of pneumonia and bacteraemia, 
as a mutant deficient in pneumolysin was severely attenuated in virulence [250, 268]. 
Moreover, pneumolysin-mediated inflammation was shown to endorse pneumococcal 
shedding and its transmission between hosts [269]. 
 
 
Pathogenesis of coinfections with influenza and pneumococci  
Preceding influenza infections significantly worsen the outcome of a secondary 
pneumococcal infection. The pathogenesis of coinfections with influenza and pneumococci is 
regulated by an interplay of viral, bacterial and host factors.  
Human influenza viruses bind to α2-6-linked Sias [174], which are found in the respiratory 
tract of men [175]. The infection with the virus induces drastic changes in the respiratory 
tract, which promote pneumococcal infections. Influenza infections foster secondary bacterial 
colonization by damaging the respiratory epithelium, which prevents ciliary clearance [270]. 
Moreover, viral sialidases have been shown to cleave Sias from epithelial surfaces and 
mucins, thereby exposing host receptors, enabling increased bacterial adhesion [271, 272], 
and providing an energy source for pneumococcal growth and translocation from the upper 
respiratory tract into the lungs [171].  
At early stages of influenza infections, the number of alveolar macrophages in the lungs are 
severely decreased [273]. It takes up to 2 weeks until the macrophage reservoir is restored by 
the infiltration of new macrophages. Thus, the host susceptibility to secondary bacterial 
infections is increased during this period [35]. Furthermore, influenza infections increase the 
production of IFN-γ, which is shown to inhibit macrophage function by downregulating 
MARCO, a scavenger receptor known to promote pneumococcal phagocytosis [274]. 
Following influenza infections, an inhibition of ROS-mediated bacterial killing by 
macrophages was also demonstrated [275]. 
Although macrophage numbers are decreased, neutrophil numbers are increased at day 7 post 
influenza infection. However, their role in bacterial influenza coinfections is still debated. 
While some studies report that increased inflammatory processes due to neutrophil influx 
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correlate with higher bacterial burden and lower survival rates in coinfected versus single 
infected mice, others described a redundancy of neutrophils in coinfection settings, as their 
depletion did not affect the disease outcome [276].  
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2 AIMS 
 
Since glycans are highly abundant in nature, they play an important role in host-pathogen 
interactions. Especially Sias, the terminal sugars of the glycan strand, serve as receptor for 
many pathogens. The main scope of this thesis was to determine virulence regulation in the 
human-adapted pathogen S. pneumoniae in response to Sias, in particular Neu5Ac and 
Neu5Gc, which are mainly abundant in humans and other mammals, respectively. Despite 
focusing on infections with pneumococci only, preceding influenza infections, which are 
known to lead to severe complications, were also taken into account. Moreover, the activation 
of host immune responses by pneumococcal glycan structures was investigated. 
 
 
2.1 SPECIFIC AIMS 
 
Paper I 
To study pneumococcal pathogenesis and the expression of virulence factors in response to 
the Sias Neu5Ac and Neu5Gc, as well as to determine how these two sugars effect 
intracellular signalling in pneumococci. 
 
Paper II 
To analyse pneumococcal interactions with Neu5Ac or Neu5Gc on host cells and to 
characterise the effect of pneumococcal toxins on the evoked host response in vitro and in 
vivo. 
 
Paper III 
To explore alterations of the host immune response in the lower respiratory tract after 
influenza infection and their consequences on coinfection with S. pneumoniae, as well as to 
investigate pneumococcal adaptations to this environment. 
 
Paper IV 
To identify pneumococcal structures that activate immune responses by dendritic cells and to 
find a possible mechanism for the enhanced cytokine secretion, observed in 
influenza/pneumococcal coinfections. 
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3 METHODOLOGICAL CONSIDERATIONS 
 
This chapter gives a general overview of infectious agents and methods that have been used 
for the work of this thesis. For a more detailed description of the protocols, see Material and 
Methods sections of the respective papers. 
 
3.1 BACTERIAL AND VIRAL STRAINS AND THEIR GROWTH CONDITIONS 
 
S. pneumoniae was cultured in C medium with yeast extract (C+Y) [277]. In some 
experimental set-ups, monosaccharide-free C+Y was supplemented with either 12 mM 
glucose, Neu5Ac or Neu5Gc. Liquid cultures or bacteria on plates were grown at 37°C in a 
water bath or at 37°C and 5% CO2 in an incubator, respectively. 
Throughout all the studies in this thesis, encapsulated and invasive pneumococcal serotype 
type 4, TIGR4 (ATCC BAA-334) [188] or its non-encapsulated derivative T4R (paper II and 
IV) [278] were used. In vitro challenges with T4R were shown to lead to similar numbers of 
phagocytosed bacteria and to comparable amounts of cytokines produced by the cells 
compared to studies using an opsonized TIGR4 [266].  
Bacterial mutants were constructed by overlap polymerase chain reaction (PCR) of the 
upstream region, an erythromycin cassette and the downstream region of the target gene 
[279]. The PCR product containing these three DNA-fragments was then transformed into 
S. pneumoniae TIGR4 or T4R, which was pre-incubated with the competence-stimulating 
peptide CSP-2 in order to induce competence. All mutations were confirmed by PCR and 
sequencing.  
Since coinfections of IAV and pneumococci are a major cause of mortality, paper III and IV 
studied different aspects of preceding influenza infections followed by pneumococcal 
challenges. In paper III, we used the mouse-adapted influenza virus strain PR8/A/34, while 
in paper IV we used the human-adapted X31. Both were propagated on Madin-Darby 
canine kidney (MDCK) cells.  
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3.2 CHARACTERIZATION OF PNEUMOCOCCAL PHENOTYPES 
 
3.2.1 Sialidase activity 
Pneumococcal sialidases are major virulence factors [209, 210]. In order to measure sialidase 
activity of bacterial lysates in paper I, a protocol by Manco et al. was used [209]. 2-O-(p-
nitrophenyl)-D-N-acetylneuraminic acid was added to the samples, followed by an incubation 
at 37°C.  Sialidases are able to cleave this substrate into Neu5Ac acid and p-nitrophenol, 
which has a yellow color. Thus, the absorbance at 405 nm was measured. The values were 
compared to a standard curve with known concentrations of the sialidase of Arthrobacter 
ureafaciens and normalized to total protein content in order to determine sialidase activity of 
the sample. 
 
3.2.2 Production of hydrogen peroxide and acetyl phosphate 
The pyruvate oxidase (SpxB) is a pneumococcal virulence factors and responsible for the 
production of H2O2 [231]. To determine amounts of H2O2 in samples of paper I and III, we 
used a previously described method [229]. 2,2´-azino-bis (3-ethylbenzthiazoline-6-sulfonic 
acid) and horseradish peroxidase were added onto the sample. After incubation at room 
temperature, the absorbance at 560 nm was measured. Total amounts of H2O2 were calculated 
with the help of a standard curve, which was produced with known concentrations of H2O2 
and normalized to bacterial numbers in the samples.  
SpxB was reported to affect intracellular acetyl phosphate (AcPh) levels [231]. In paper I, 
AcPh content inside the bacterial cell was studied according to the protocol by Pruss and 
Wolfe [280]. In order to measure total AcPh amounts, it was used to convert adenosine 
diphosphate (ADP) to adenosine triphosphate (ATP) by an acetate kinase, and quantified 
using a bioluminescence kit. Finally, the results were compared to a standard curve with 
known AcPh amounts and normalized to total protein in the sample. 
 
3.2.3 Survival in response to hydrogen peroxide 
Although pneumococci have been shown to be catalase-negative, they developed 
mechanisms to resist ROS [84, 234]. To study the sensitivity of pneumococci to H2O2 in 
paper I and III, the method published by Ibrahim et al. was used [220]. Bacteria were 
incubated in the presence of H2O2 at 37°C. The percentage of surviving bacteria was 
calculated by dividing viable bacterial numbers after exposure by viable bacterial numbers 
before exposure to H2O2.  
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3.3 IN VITRO AND EX VIVO MODELS 
 
3.3.1 Cells 
Since S. pneumoniae is a human-adapted pathogen [281], we performed most of the in vitro 
experiments with human cell lines or compared cells with either Neu5Ac- or Neu5Gc-
containing glycoconjugates. 
In paper II, human cell lines THP-1 (ATCC TIB-202) and A549 (ATCC CCL-185) derived 
from acute monocytic leukemia or epithelial lung cell carcinoma, respectively, were used. 
To differentiate THP-1 cells into macrophage-like cells, they were incubated with phorbol 
myristate acetate. Cell lines present a good in vitro model in order to mimic the in vivo 
setting. However, the immortalization of the cells can also lead to differences in their 
phenotype, e.g. receptor expression levels. Therefore, we additionally performed 
experiments with primary alveolar macrophages, which were isolated from the BAL from 
uninfected C57BL/6 wild-type (wt) or Cmah-/- mice. While wt mice mainly present Neu5Gc 
on the surface of their cells, Cmah-/- mice have a human like deletion in exon 6 of the Cmah 
gene [282], leading to the lack of Neu5Gc. 
In paper IV, primary monocytes from buffy coats of healthy human donors were isolated 
and cultured with granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4 
to differentiate them into DCs. Successful differentiation was confirmed by the presentation 
of the surface markers CD1a  and CD11c.  
Human embryonic kidney 293 cells (HEK293, ATCC CRL-1573) were used in paper IV. 
These cells were stably transfected with plasmids either expressing TLR3 or TLR4 and 
luciferase.  
 
3.3.2 Sialic acid feeding of cells 
The Sia profiles differ greatly between humans and most other mammals [133, 134]. To study 
the effect of Neu5Ac- and Neu5Gc-presentation by host cells on pneumococcal virulence in 
paper II, a previously published method was used [283, 284]. We supplemented the RPMI 
1640 cell medium with Neu5Ac and heat-inactivated human AB serum or Neu5Gc and heat-
inactivated fetal bovine serum. The Neu5Ac- and Neu5Gc-presention by the cells was 
confirmed by staining with Sambucus nigra lectin (SNA), Maackia amurensis lectin II (MAA 
II) and an antibody raised against Neu5Gc. 
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3.3.3 Measurement of cytokine response and cell toxicity 
In all papers, pro-inflammatory cytokines, like human or murine TNFα or interleukin 6 (IL-
6), IL-12, and chemokines, like human IL-8 or murine KC or macrophage inflammatory 
protein 2 (MIP-2), were determined in cell supernatants or BAL of mice using enzyme-linked 
immunosorbent assay (ELISA). 
 
3.4 IN VIVO MODELS 
Pneumococci have humans as their natural host [281] but different animal models, like rats 
and mice, have been described as a suitable model to study pneumococcal infections [285]. In 
vivo models allow studying pneumococcal-host interactions in a complex environment, which 
also takes the immune system as a whole into account. In paper I, II and III, wt and/or Cmah-
/- mice have been used. Besides, diminishing the synthesis of Neu5Gc, an inactivation of 
Cmah in the mice caused age-related hearing loss and defects in wound healing without 
affecting the recruitment of immune cells [282]. Similar to humans, Cmah-/- mice are also 
demonstrated to exhibit an over-reacting immune system [143, 144]. A recently reported 
dock2 mutation in some Cmah-/- mice, which occurred due to backcrossing into 
commercially available C57BL/6 mice [286], was not present in the mice used in this 
thesis. 
In paper I and II, mice were infected intransally with 20 µl PBS containing S. pneumoniae, 
presenting the natural route of infections by pneumococci. About half of the inoculum 
reached the lungs directly during infection, allowing us to study the development of 
pneumonia and the progress into septicaemia in the mice. In paper I, we also infected the 
mice intravenously, in order to study pneumococcal infections in the blood stream. In paper 
III, we challenged the mice intranasally with influenza. To study pneumococcal/influenza 
coinfections, pneumococci were instilled intratracheally, which allowed us to deliver the 
whole bacterial inoculum into the lower respiratory tract.  
 
3.5 ETHICAL CONSIDERATIONS 
All experiments were performed in accordance with the local ethical committee 
(Stockholms Norra djurförsöksetiska nämnd). Mice were kept with food and water ad 
libitum and 12 hours light/dark cycles. The health status of the mice was controlled 
regularly. 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
 
Streptococcus pneumoniae senses a human-like sialic acid profile via the response 
regulator CiaR 
When pulmonary pathogens, like S. pneumoniae, enter the respiratory tract, they come in 
contact with Sias in mucins [166, 287]. Pneumococci are adapted to humans as their natural 
host [281]. Thus, the first study included in this thesis determined pneumococcal virulence 
in response to the Sias Neu5Ac and Neu5Gc, which are predominantly found in mucins of 
humans or of most other mammals, respectively. Moreover, we compared expression levels 
of pneumococcal virulence factors in response to these sugars and elucidated how Sia 
catabolism affects intracellular signalling in pneumococci.  
To study pneumococcal pathogenesis in response to Neu5Ac and Neu5Gc, we challenged 
C57BL/6 wt and Cmah-/- mice with pneumococci. While wt mice are able to convert Neu5Ac 
to Neu5Gc, Cmah-/- mice, like humans, overproduce Neu5Ac and are not able to synthetize 
Neu5Gc [282, 288]. We chose an in vivo model of intranasal challenge, since it presents the 
natural route of infection by pneumococci. At 24 hours post infections, we detected 
significantly higher bacterial numbers in lungs, BAL and the blood as well as reduced 
survival rates of Cmah-/- compared with wt mice. Hence, pneumococci trigger stronger 
symptoms of disease in Cmah-/- mice in comparison to wt mice. In agreement with our results 
Trappetti and colleagues observed higher bacterial counts in the lungs of mice after intranasal 
administration of Neu5Ac but not Neu5Gc [170].  
 
Besides being able to utilize Neu5Ac as carbon source [172, 197], our data indicate that S. 
pneumoniae can also grow on Neu5Gc. Since pneumococci are human-adapted pathogens, 
we propose that pneumococcal virulence factors mediate increased virulence in response to 
human-like Sia profiles compared to Neu5Gc. We decided to study the activity of sialidases, 
since pneumococcal sialidase NanA was shown to bind to Sia and to remove it from the 
glycan strand [178]. Moreover, sialidases of other bacteria, viruses and mammals have been 
reported to preferentially adhere to and cleave Neu5Ac- compared with Neu5Gc-containing 
substrates [289-291]. To catabolize Sia, it needs to be taken up into the bacterial cell [172] 
and both NanA and the main Sia transporter SatABC have recently been demonstrated to be 
upregulated in response to Neu5Ac [189, 200]. We isolated pneumococcal RNA from in vitro 
conditions using monosaccharide-free C+Y medium supplemented with either Neu5Ac or 
Neu5Gc, and in vivo from the nasopharynx of wt and Cmah-/- mice. NanA transcription, as 
well as sialidase activity was increased in Neu5Ac-incubated bacteria compared to Neu5Gc-
treated ones. Moreover, bacteria isolated from the nasopharyngeal lavage of Cmah-/- mice had 
higher nanA mRNA levels in comparison to those isolated from wt mice. Additionally, the 
substrate binding protein SatA of the main Sia transporter was also higher transcribed in 
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response to Neu5Ac as compared with Neu5Gc. The differential transcription of nanA in 
TIGR4 in response to the two sugars was dependent on the three known Sia transporters, 
SatABC, SP1688-90, and SP1328 [184, 187], which suggest that pneumococci upregulate 
virulence factors in response to Neu5Ac compared with Neu5Gc after it has been taken up 
into the bacterial cell.  
 
To test whether pneumococcal TCS are involved in the Sia-mediated signalling, we 
monitored transcription rates of all known pneumococcal RR, as well as growth rates of their 
deletion mutants on Sia and glucose. Our data reveal that a mutant deficient in CiaR had 
severe growth defects on Neu5Ac and Neu5Gc but not on glucose.  Moreover, mRNA 
expression of RR05, also known as CiaR, was increased in bacteria treated with Neu5Ac 
compared with Neu5Gc but only if the Sia transporters were present. Hence, we hypothesized 
that this RR could be involved in intracellular signalling in response to Sia or its metabolic 
compounds. The TCS CiaRH is known to control the expression of HtrA, which mediates 
pneumococcal resistance to oxidative stress [234]. Consequently, we measured htrA 
transcription and pneumococcal survival in response to H2O2 and found both to be increased 
after incubation in Neu5Ac compared with Neu5Gc. 
CiaR needs to be phosphorylated in order to bind to target promoter sequences [228]. 
Interestingly, it was shown that its phosphorylation does not depend on the HK CiaH, instead 
intracellular AcPh can also serve as phosphor-donor [230]. In pneumococci, the pyruvate 
oxidase SpxB is the main producer of AcPh and H2O2 [229, 231]. Moreover, its expression 
was shown to affect CiaR transcription [230]. After treatment with Neu5Ac, we observed 
higher spxB transcription as well as increased H2O2 and AcPh amounts inside pneumococci 
in comparison to Neu5Gc treatment. Noteworthy, an spxB-deficient mutant did not only 
downregulate ciaR transcription, it also decreased nanA levels significantly. 
 
CiaR, NanA as well as SatABC are well-known pneumococcal virulence factors [172, 209, 
210, 215, 292]. While intranasal infections with wt TIGR4 resulted in higher bacterial 
numbers in the lungs and blood of Cmah-/- compared with wt mice, challenges with 
TIGR4∆ciaR, TIGR4∆nanA or TIGR4∆satABC led to comparable cfu in the lungs of wt and 
Cmah-/- mice without invading into the bloodstream. Thus, CiaR, NanA and SatABC 
contribute to a more severe outcome of pneumococcal disease in Cmah-/- compared with wt 
mice. 
 
In TIGR4, the genes required for Sia retrieval and metabolism are encoded in the nanAB and 
the nanC loci [178, 184]. The nanAB locus harbours catabolite repression elements [189, 
200], which suppress the transcription of genes inside the locus in the presence of glucose. 
Also, CiaR is reported to be downregulated in response to glucose [293]. Since we did not 
observe any differences in bacterial numbers and survival rates between wt and Cmah-/- mice 
after intravenous challenge, we propose that NanA, SatABC and CiaR facilitate a faster 
disease progression in the glucose-free respiratory tract [294] of Cmah-/- compared with wt 
mice, but not in the blood stream with high glucose concentrations [295]. 
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This study demonstrates a possible mechanism for increased pneumococcal virulence in 
response to Neu5Ac in contrast to Neu5Gc. Our data indicate that pneumococci are able to 
signal in response to Sias via the RR CiaR. We propose a model, in which the presence of 
Neu5Ac increases expression of sialidase NanA and Sia transporter SatABC, leading to 
increased scavenging of Sias and higher amounts of Sia or its metabolic products, e.g. 
pyruvate, inside the bacterial cell. Subsequently, SpxB expression is upregulated, leading to 
enhanced levels of AcPh and H2O2. Increased AcPh amounts inside the bacterial cell 
upregulate CiaR, which mediates increased resistance to ROS via HtrA and upregulates 
NanA expression.  
  
 36 
4.2 PAPER II 
 
Human sialic acid profiles mediate increased pneumococcal adhesion and immune 
evasion 
The second study of this thesis further characterised pneumococcal host tropism. Since we 
observed an upregulation of pneumococcal virulence factors in response to Neu5Ac as 
compared with Neu5Gc in paper I, we aimed at investigating how pneumococci interact with 
Neu5Ac- or Neu5Gc-presenting host cells and how this interplay affects the host’s immune 
response. 
Since it was shown that virulence factors of several human-adapted pathogens favourably 
bind to human-like sialic acid profiles [140, 142], we set up an in vitro model to study 
pneumococcal interactions with cells presenting either Neu5Ac or Neu5Gc. Sia feeding has 
been reported to modify glycan structures of several cell lines [283, 284]. We used 
macrophage-like THP-1 cells and a lung epithelial cell line (A549). By supplementing the 
cell culture media with Neu5Ac and human serum or Neu5Gc and fetal calf serum, we could 
detect α2-3- and α2-6-linked Sias by staining the cells with the lectins MAAII and SNA, 
respectively. However, only after Neu5Gc supplementation could Neu5Gc be detected on the 
surface of both cell lines using anti-Neu5Gc antibodies. In contrast, cells that were cultured in 
the presence of Neu5Ac were not recognized by the anti-Neu5Gc antibody. We propose that 
they most likely present Neu5Ac, although this remains to be experimentally confirmed.  
Next, we studied whether Neu5Ac- or Neu5Gc-supplementation of the growth media affects 
pneumococcal adhesion to cells. We used a non-encapsulated variant of TIGR4, T4R, since it 
was shown to behave similar to opsonized wt TIGR4 in in vitro phagocytosis assays [266]. 
By performing cell adhesion and uptake assays, we detected higher numbers of cell-
associated bacteria when cells were cultured in the presence of Neu5Ac as compared with 
Neu5Gc. However, we excluded the pneumococcal capsule as determinant of this phenotype, 
as both wt TIGR4 and T4R adhered better to Neu5Ac- than to Neu5Gc-incubated cells. To 
test whether increased pneumococcal adhesion to Neu5Ac as compared with Neu5Gc-
presenting cells, can be extrapolated to primary cells, we isolated primary alveolar 
macrophages from uninfected wt and Cmah-/- mice. After challenging the cells with 
pneumococci, we observed higher adhesion rates to macrophages from Cmah-/- compared 
with those from wt mice.  
The pneumococcal pyruvate oxidase SpxB and pneumolysin are potent virulence factors and 
stimulate inflammatory processes [236]. In line with observations of other groups, we 
detected lower adhesion rates of spxB and pneumolysin deficient mutants compared with wt 
bacteria [263, 296]. Since inflammatory processes are reported to alter the glycan structures 
on host cells [164, 165], we proposed that these pneumococcal cytotoxins could upregulate 
glycosylations on cells and hence provide additional attachment sites for bacteria. Moreover, 
mutants in spxB produce significantly lower AcPh amounts than wt bacteria [297]. AcPh is 
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shown to be able to phosphorylate RR CiaR, a major pneumococcal regulator [230], thus 
expression levels of adhesins might also be reduced. It will be interesting to test which 
pneumococcal adhesins favourably bind to Neu5Ac than to Neu5Gc. 
More bacteria also lead to higher levels of pneumococcal virulence factors, like SpxB or 
pneumolysin. Recently, it was shown that the presence of SpxB and pneumolysin cause host 
cell apoptosis [210, 237, 250, 297, 298]. Consequently, the increased bacterial burden on 
Neu5Ac-incubated cells might cause higher cytotoxicity in comparison to lower bacterial 
numbers associated with Neu5Gc-fed cells.  
Like T4R, mutants in spxB and pneumolysin adhered better to Neu5Ac- than to Neu5Gc-
cultured cells. T4R and T4RΔspxB were also taken up more into Neu5Ac- compared to 
Neu5Gc-treated cells. In contrast, there was no significant difference in phagocytosis of 
T4RΔply between Neu5Ac- and Neu5Gc-fed cells. Since pneumolysin has been 
demonstrated to bind to sialylated carbohydrates on cells [254], we speculate that 
extracellular pneumolysin facilitates higher pneumococcal adhesion to Neu5Ac as compared 
with Neu5Gc on host cells.  
To study the host’s immune response, we measured the production of IL-8 after 
pneumococcal infection of Neu5Ac or Neu5Gc-incubated THP-1 cells. IL-8 concentrations 
were reduced in cells fed with Neu5Ac compared with Neu5Gc after challenge with T4R and 
T4RΔspxB but not after infection with T4RΔply. It is tempting to speculate that lower IL-8 
levels are caused by higher cytotoxicity in Neu5Ac-fed cells, but this remains to be tested.  
To determine the importance of Neu5Ac- and Neu5Gc-presenting cells in pneumococcal 
infections in vivo, we challenged wt and Cmah-/- mice intranasally with TIGR4, 
TIGR4ΔspxB or TIGR4Δply. We observed similar bacterial numbers in BAL of wt and 
Cmah-/- mice after challenge with TIGR4 or its isogenic mutants in spxB or pneumolysin. 
However, we detected lower total cell numbers, fewer neutrophils as well as lower MIP-2 
and TNFα concentrations in BAL of Cmah-/- compared with wt mice after challenge with 
TIGR4 but not after infection with TIGR4ΔspxB or TIGR4Δply. KC concentrations were 
lower in Cmah-/- than in wt mice after infection with TIGR4 and TIGR4ΔspxB. Infections 
with TIGR4ΔspxB or TIGR4Δply almost did not cause any neutrophil influx in the BAL. 
To exclude an immunodeficiency of Cmah-/- mice, we administered LPS intranasally into 
wt and Cmah-/- mice. Both mice showed a similar immune response and recruited 
comparable numbers of cells into the airway.  
 
In summary, we observed higher pneumococcal adhesion rates to cells expressing human-
like Sia profiles. Moreover, higher bacterial numbers resulted in lower IL-8 secretion, 
which was mainly mediated by the pneumococcal cytotoxin pneumolysin. A recently 
published study reported that also E. coli adheres better to cells of Cmah-/- than wt mice. 
The authors observed increased bacterial killing after infecting macrophages of Cmah-/- 
mice with sublethal doses of E.coli but a higher susceptibility to endotoxins in the knock-
out mice after intraperitoneal challenge. They hypothesized that the CMAH loss provided 
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an advantage to clear minor infections, while it can be harmful during severe infections 
[135]. 
 
In line with our in vitro data, we observed lower cytokine and chemokine concentrations as 
well as lower numbers of infiltrating neutrophils in the BAL of Cmah-/- than in wt mice 
after challenge with TIGR4. Thus, we propose that higher pneumococcal adhesion rates to 
alveolar epithelial cells and/or macrophages of Cmah-/- mice compared with wt mice 
mediate increased cytotoxicity in the knockout mice. Macrophages and epithelial cells 
produce cytokines and chemokines, which evoke an influx of neutrophils to the site of 
infection. Hence, higher cell death rates in these cells might lead to lower secretion rates of 
inflammatory mediators and lower numbers of recruited neutrophils. However, further 
experiments are required to test this hypothesis. 
 
Additionally, our data indicate that using cell culture medium supplemented with fetal 
bovine serum in in vitro assays might skew the experimental outcome for human-adapted 
pathogens, as they might preferentially bind to Neu5Ac and not to Neu5Gc. 
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4.3 PAPER III 
 
Mechanism for enhanced bacterial burden in the lower respiratory tract of mice during 
influenza/pneumococcal coinfection 
The third study of this thesis determined influenza-mediated alterations in the respiratory tract 
and their consequences for pneumococcal adaptation and virulence regulation.  
To set up an in vivo model for studying influenza/pneumococcal coinfections, we challenged 
mice with pneumococci 7 days post influenza infection. At this time point, the mice were 
recovering from the primary influenza infection. Additionally, humans are also shown to be 
highly susceptible to bacterial superinfections about one week post influenza infection [299]. 
In line with earlier publications [274, 300], we detected higher bacterial burden in the BAL of 
influenza/pneumococcal coinfected mice compared to those, which were challenged with 
pneumococci only. 
Viral sialidases are known to cleave terminal Sias from the glycan strand [301], hence they 
increase the concentration of free Sia in the respiratory tract. Siegel and colleagues showed 
that pneumococci utilize virus-released Sias in the nasopharynx, which promotes 
pneumococcal colonization and translocation into the lungs [171]. To test whether free Sias 
also foster pneumococcal dissemination in the lower respiratory tract (LRT), we infected 
mice with TIGR4 and its isogenic mutant in the main Sia transporter SatABC. Like wt 
TIGR4, infections with a satABC-deficient mutant led to increased bacterial numbers in the 
BAL and lungs of coinfected compared with single-infected mice. Hence, pneumococcal 
outgrowth in the LRT is independent on growth on Sia. 
To determine total numbers of immune cells and to investigate their contribution to the host 
response in the LRT, we isolated cells from BAL of untreated, influenza infected, 
pneumococcal challenged and coinfected mice. As it was reported by other groups [273], the 
number of macrophages was decreased in influenza and coinfected mice, which might 
contribute to a defect in bacterial clearance [273, 274, 302, 303]. In contrast, cytokine release 
and neutrophil numbers were increased after challenge with influenza and in coinfected mice. 
Thus, although bacterial clearance might be reduced, recruitment of neutrophils and cytokine 
secretion mechanisms seem to be functional in our model. 
AMPs are known to play an importance role in the innate immune response to invading 
pathogens. To measure the production of AMPs and collectins in alveolar macrophages, 
neutrophils and epithelial cells, we isolated RNA from lung tissue and transcription of cramp, 
BD1, BD3, SP-A and SP-D. At day 7 post influenza challenge, transcription of cramp, bd1 
and sp-A was significantly reduced in comparison to uninfected mice. In coinfected mice, 
mRNA levels of cramp and bd1 were strongly decreased. These findings are coherent with 
another study, which reported a downregulation of antimicrobial proteins and peptides in 
coinfected versus single-infected lungs [304]. Interestingly, we found increased protein 
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expression of cramp in influenza and coinfected mice compared to uninfected and single-
infected ones. On one hand, increased cell death in the respiratory tract can lead to lower 
production levels of antimicrobial peptides and proteins. On the other hand, recruited 
neutrophils already contain cramp and release it, thus leading to a negative feedback, which 
inhibits cramp transcription and helps to prevent host cell damage [305]. 
It is well-known that influenza infections lead to increased oxidative stress in the LRT [306]. 
To study the effect of influenza-mediated ROS production by immune cells on pneumococcal 
virulence, we determined concentrations of H2O2 in BAL of uninfected and influenza 
challenged mice. After infection with influenza, we detected higher H2O2 levels in BAL than 
in uninfected mice. Since pneumococcal resistance to ROS is regulated by the serine protease 
HtrA [234], we measured htrA transcription and found it to be increased in response to 
influenza-infected BAL compared to uninfected BAL. Hence we suggest that influenza leads 
to enhanced stress in form of denatured proteins and increased ROS in the LRT, which 
upregulates pneumococcal HtrA. Furthermore, in paper I we found a Sia-mediated 
upregulation of HtrA. Influenza infections increase the level of free Sia in the airway of 
infected mice [171], and thus could also mediate HtrA upregulation in pneumococci 
incubated in BAL of influenza-infected animals.   
Genes involved in the regulation of oxidative stress have been shown to be important during 
coinfections of influenza and H. influenzae [307]. However, we did not find any study, which 
examined the role of HtrA in influenza/pneumococcal coinfections. The serine protease HtrA 
is surface exposed [241] and a well-known pneumococcal virulence factor [248]. It is 
demonstrated to have chaperone and protease functions, as it aids protein folding at lower 
temperatures, and degrades misfolded proteins under stress conditions [242]. Moreover, it has 
been demonstrated to degrade E-cadherin, thus fostering bacterial invasion across epithelial 
barriers [246, 247]. We detected higher protein concentrations and increased numbers of dead 
cells in the LRT of influenza infected mice at day 7 post infections. Thus, we hypothesized 
that pneumococci might metabolize and grow on denatured proteins and cell debris. To test 
the role of HtrA in a coinfection setting, we infected mock and influenza-challenged mice 
with TIGR4ΔhtrA and observed severely reduced bacterial numbers in the LRT of coinfected 
in contrast to single-infected mice. 
The TCS CiaRH is reported to control transcription of htrA in vitro [218, 219]. In contrast to 
infections with TIGR4ΔhtrA, infections with a ciaR-deficient mutant led to similar bacterial 
numbers as challenges with wt TIGR4. Moreover, our results suggest that HtrA is required to 
cope with stress in the LRT post influenza challenge and that htrA transcription can be 
controlled independently of CiaR in the lungs of coinfected mice. Interestingly, RR09 has 
been implicated in pneumococcal virulence, as well as in regulation of HtrA expression 
[308]. Future studies will show, if RR09 is responsible for the upregulation of HtrA in vivo in 
the absence of CiaR. 
In summary, our data suggest that influenza-mediated changes of the host environment in the 
LRT support secondary pneumococcal infections by promoting pneumococcal adaptation and 
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upregulating pneumococcal virulence factors, like HtrA. Moreover, HtrA facilitates 
pneumococcal outgrowth during influenza/pneumococcal coinfections, which indicates its 
importance as a therapeutic target.  
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4.4 PAPER IV 
 
Toll-like receptor 3/TRIF-dependent IL-12p70 secretion mediated by Streptococcus 
pneumoniae RNA and its priming by influenza A virus coinfection in human dendritic 
cells 
The last study of this thesis describes the recognition of pneumococcal RNA by TLR3 and 
presents a mechanism for the increased IL-12 production in DCs upon 
influenza/pneumococcal coinfection.  
DCs are shown to be the main producers of IL-12p70. After pneumococcal infections, IL-12 
activates TH1-cells and stimulates the production of IFN-γ by other immune cells [115-117]. 
IL-12 plays an important role in vivo, as its exogenous administration improved the disease 
outcome in a murine model of pneumococcal pneumonia [309]. Moreover, IL-12 deficiency 
in humans was associated with recurrent pneumococcal infections [310]. To examine the role 
of this cytokine in pneumococcal infections in monocyte-derived DCs, we challenged these 
cells with a low infection dose of T4R. A MOI of 1 did not affect cytotoxicity but evoked a 
secretion of IL-12p70 by DCs, which was dependent on pneumococcal uptake. 
Next, we aimed at studying the role of TRIF in pneumococcal infections of DCs. TLR3 and 
TLR4 are the only PRRs that signal via TRIF, while other TLRs use MyD88 as adapter 
molecule to stimulate host responses [61, 62]. We silenced TRIF in DCs using small 
interfering RNAs and challenged the cells with T4R to measure IL-12p70 production. RNA 
as well as protein levels of IL-12 were decreased. Hence, DCs sense pneumococci via TRIF-
mediated TLR-signalling.  
To determine the role of TLR4 in pneumococcal sensing by DCs, we next silenced TLR4 in 
these cells and measured IL-12p70 secretion. While there are studies implicating 
pneumococcal toxin pneumolysin in the activation of TLR4 [67, 311-313], other research 
groups have observed a TLR4-independent sensing of pneumolysin [71, 251, 314]. Our data 
indicate that pneumococci can activate DCs independently of TLR4 expression in this model, 
as IL-12 transcription and secretion were not affected by inactivation of this PRR. 
Next, we silenced TLR3 in DCs and measured IL-12p70 production after pneumococcal 
challenge. Interestingly, we found a decrease of this cytokine on transcriptional as well as on 
protein level. To confirm this result, we made use of a TLR3/dsRNA complex inhibitor, 
which reduced the secretion of IL-12. The capsule did not interfere with this result, as we 
observed a downregulation of IL-12 release even after challenge with wt TIGR4. These 
results show that DCs recognize pneumococci via the endosomal receptor TLR3.  
A previous study by our group reported an IAV-mediated type I IFN production, which led to 
an enhanced secretion of IL-12 by neighbouring DCs [315]. Moreover, viral infections as 
well as type I IFN are known to upregulate TLR3 expression [316, 317]. To explore whether 
IAV upregulates TLR3 and consequently leads to an increase of IL-12p70 secretion in 
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influenza/pneumococcal coinfections, we measured mRNA levels of TLR3 in DCs 
challenged with influenza alone and after influenza/pneumococcal coinfection. Indeed, TLR3 
expression was enhanced in IAV infected and coinfected DCs. Moreover, we tested IL-12p40 
transcription and found it to be upregulated in T4R single-infected and even more in 
IAV/T4R coinfected DCs. However, treatment with IFN-α alone only had a minor effect on 
TLR3 expression, suggesting that additional factors other than IFN-α might contribute to the 
influenza-induced TLR3 upregulation. 
TLR3 is known to recognize viral dsRNA [62]. However, there are recent reports describing 
TLR3-mediated sensing of bacterial RNA [318-320]. To test whether pneumococcal RNA is 
sufficient to induce TLR3-mediated IL-12p70 production, we isolated RNA from T4R and 
transfected it into DCs. We observed an induction of IL-12p70 secretion upon transfection 
with total RNA, which was dependent on TLR3 and completely abolished after RNAse-
treatment. Furthermore, we confirmed RNA-mediated TLR3 activation in HEK293 cells 
expressing TLR3. 
Additionally, we killed pneumococci by heat exposure and UV radiation and found the latter 
condition to induce IL-12p70 secretion. We determined the RNA quality after the two 
treatments and found the RNA to be degraded after heat treatment, while UV radiation 
maintained RNA integrity. Moreover, our data show that RNAse treatment of UV-killed 
pneumococci reduced cytokine secretion in a dose-dependent manner, while DNAse 
treatment and LPS transfection in combination with RNAse did not affect IL-12 production. 
In summary our data indicate that pneumococci are taken up into DCs and degraded inside 
the endosome. Released pneumococcal RNA can subsequently be sensed by TLR3 and 
induces secretion of IL12-p70. Furthermore, our results give a possible explanation for the 
increased cytokine secretion in influenza/pneumococcal coinfection. The data suggest that 
infections with influenza lead to the secretion of type I IFN and other factors, which enhances 
TLR3 expression by DCs. Consequently, the higher level of TLR3 mediate increased IL12-
p70 production in response to secondary pneumococcal infections. 
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5 CONCLUDING REMARKS 
 
S. pneumoniae is a major threat to human health, especially of very young, elderly and 
immunocompromised individuals. Even though vaccines and antibiotics are available today, 
the emergence of non-vaccine types in IPD and antibiotic resistance in pneumococci demand 
for the development of improved vaccines and therapeutics. Consequently, a comprehensive 
understanding of pneumococcal-host interactions is required.  
Immediately after entering the host, pulmonary pathogens, like S. pneumoniae or IAV, come 
in contact with glycans, which serve as receptors for adhesion [166] and thus present a 
prerequisite for pathogenesis. In the case of pneumococci, sugars of the glycan strand can 
also act as carbon source [172, 197, 293]. S. pneumoniae allocates more than 30% of all 
transporters to the uptake of carbohydrates [188], which points towards the importance of 
carbohydrates in pneumococcal colonization and disease. Sialic acid, the terminal sugar of 
the glycan strand, has been implicated in pneumococcal metabolism but has also been 
demonstrated to serve as a signal for pneumococcal disease [170, 172]. However, there is also 
another aspect of glycan-based host-pathogen interactions, as most PAMPs are demonstrated 
to be microbial glycan structures, and thus activate innate immune responses [181]. 
In paper I and II, we study sialic acid-mediated aspects of pneumococcal host tropism. In 
paper I, we demonstrate that pneumococci upregulate several virulence factors in response to 
Neu5Ac, the sialic acid mainly abundant in humans, compared with Neu5Gc, which cannot 
be synthesized by humans. Moreover, we show that sialic acid or its metabolic products are 
sensed involving the pneumococcal response regulator CiaR. In paper II, we show an 
increased pneumococcal adhesion rate to Neu5Ac– compared with Neu5Gc-containing host 
glycans. Moreover, we present data indicating a role of pneumococcal cytotoxins in increased 
immune evasion by pneumococci in response to Neu5Ac compared with Neu5Gc. 
In paper III and IV, we study pneumococcal-host interactions after prior influenza infections, 
since they account for severe disease outcomes. In paper III, we determine influenza-induced 
changes in the LRT of mice and investigate pneumococcal adaptations to this environment. In 
paper IV, we show that pneumococcal RNA can be sensed by TLR3 in DCs. Moreover, in a 
coinfection setting, influenza infections increase TLR3 expression with the help of type I 
interferon. Thus upon secondary pneumococcal challenge, enhanced TLR3 expression 
upregulates IL-12 production. 
In summary, we show that glycans play a pivotal role in pneumococcal pathogenesis. The 
studies included in this work give insights into alterations of pneumococcal-host interactions 
caused by differences in the sialic acid profile of humans in comparison to other mammals, as 
well as by preceding viral infections. Moreover, this thesis describes the activation of the 
innate immune system by pneumococcal glycan-based structures, like RNA. These findings 
will hopefully add to the improvement of current treatment options and to the development of 
new vaccines. 
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